These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34162364)

  • 21. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Deeks JJ; Adriano A; Berhane S; Davenport C; Dittrich S; Emperador D; Takwoingi Y; Cunningham J; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Taylor-Phillips S; Hooft L; Leeflang MM; Spijker R; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013705. PubMed ID: 32845525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia.
    Enticott J; Gill JS; Bacon SL; Lavoie KL; Epstein DS; Dawadi S; Teede HJ; Boyle J;
    BMJ Open; 2022 Jan; 12(1):e057127. PubMed ID: 34980631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunity passports to travel during the COVID-19 pandemic: controversies and public health risks.
    Liew CH; Flaherty GT
    J Public Health (Oxf); 2021 Apr; 43(1):e135-e136. PubMed ID: 32756915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in preventive behaviour after COVID-19 vaccination in Thailand: a cross-sectional study.
    Ngamchaliew P; Kaewkuea N; Nonthasorn N; Vonnasrichan T; Rongsawat N; Rattanachai L; Chaipipattanakij W; Kamolnawin S; Vichitkunakorn P
    BMC Public Health; 2022 Nov; 22(1):2039. PubMed ID: 36348474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of COVID-19 Certificates: A Qualitative Study in Geneva, Switzerland, in 2020.
    Fargnoli V; Nehme M; Guessous I; Burton-Jeangros C
    Front Public Health; 2021; 9():682365. PubMed ID: 34485215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
    Pizarro AB; Persad E; Durao S; Nussbaumer-Streit B; Engela-Volker JS; McElvenny D; Rhodes S; Stocking K; Fletcher T; Martin C; Noertjojo K; Sampson O; Verbeek JH; Jørgensen KJ; Bruschettini M
    Cochrane Database Syst Rev; 2022 May; 5(5):CD015112. PubMed ID: 35514111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative analysis of COVID-19 vaccination certificates in 12 countries/regions around the world: Rationalising health policies for international travel and domestic social activities during the pandemic.
    Wang B; Ping Y
    Health Policy; 2022 Aug; 126(8):755-762. PubMed ID: 35680529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of COVID-19 certification mandates on the number of cases of and hospitalizations with COVID-19 in the UK: A difference-in-differences analysis.
    López-Güell K; Prats-Uribe A; Català M; Prats C; Hein J; Prieto-Alhambra D
    Front Public Health; 2023; 11():1019223. PubMed ID: 36908465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Travel-related control measures to contain the COVID-19 pandemic: a rapid review.
    Burns J; Movsisyan A; Stratil JM; Coenen M; Emmert-Fees KM; Geffert K; Hoffmann S; Horstick O; Laxy M; Pfadenhauer LM; von Philipsborn P; Sell K; Voss S; Rehfuess E
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013717. PubMed ID: 33502002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of a Vaccine Passport Validation System Using Blockchain-based Architecture: Development Study.
    Lee HA; Wu WC; Kung HH; Udayasankaran JG; Wei YC; Kijsanayotin B; Marcelo AB; Hsu CY
    JMIR Public Health Surveill; 2022 Apr; 8(4):e32411. PubMed ID: 35377316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving towards Digitising COVID-19 Vaccination Certificate: A Systematic Review of Literature.
    Kissi J; Kusi Achampong E; Kumasenu Mensah N; Annobil C; Naa Lamptey J
    Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
    Manali M; Bissett LA; Amat JAR; Logan N; Scott S; Hughes EC; Harvey WT; Orton R; Thomson EC; Gunson RN; Viana M; Willett B; Murcia PR
    J Infect Dis; 2022 Dec; 227(1):40-49. PubMed ID: 35920058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventions to increase COVID-19 vaccine uptake: a scoping review.
    Andreas M; Iannizzi C; Bohndorf E; Monsef I; Piechotta V; Meerpohl JJ; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015270. PubMed ID: 35920693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Social Distance in COVID-19: Drawing the line between protective behavior and stigma manifestation.
    Economou M
    Psychiatriki; 2021 Sep; 32(3):183-186. PubMed ID: 34390552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns.
    Sharun K; Tiwari R; Dhama K; Rabaan AA; Alhumaid S
    Hum Vaccin Immunother; 2021 Nov; 17(11):4108-4111. PubMed ID: 34292128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.
    Stevenson M; Metry A; Messenger M
    Health Technol Assess; 2021 Jun; 25(39):1-74. PubMed ID: 34142943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.